hepat
b
viru
hbv
infect
major
worldwid
health
problem
caus
acut
chronic
hepat
significantli
increas
risk
liver
cirrhosi
primari
hepatocellular
carcinoma
hcc
nowaday
clinic
therapi
hbv
infect
still
mainli
reli
nucleotid
analog
interferon
usag
limit
drugresist
mutat
side
effect
defensin
report
effect
inhibit
prolifer
bacteria
fungi
parasit
virus
screen
antihbv
activ
scorpionderiv
peptid
recent
character
group
evalu
antihbv
activ
cytotox
found
scorpion
defensin
antibacteri
activ
compar
high
inhibitori
rate
hbeag
hbsag
cultur
medium
low
cytotox
experiment
result
show
dosedepend
decreas
product
hbv
dna
hbv
viral
protein
cultur
medium
cell
lysat
interestingli
exert
high
serum
stabil
togeth
studi
indic
scorpion
defensin
also
inhibitori
activ
hbv
replic
along
antibacteri
potassium
ion
channel
activ
show
uniqu
multifunct
defensin
molecul
work
also
provid
good
molecul
materi
use
investig
link
relationship
antivir
antibacteri
ion
channelmodul
activ
futur
hepat
b
viru
hbv
prototyp
member
hepadnavirida
pathogen
caus
acut
chronic
type
b
hepat
human
chronic
hbv
infect
affect
health
million
peopl
around
world
demonstr
result
elev
risk
develop
hepatocellular
carcinoma
hcc
although
effect
vaccin
extens
appli
year
increas
amount
infect
individu
difficulti
treatment
infect
still
perplex
physician
research
nucleotid
analogu
avail
allevi
patient
condit
therapeut
applic
serious
limit
side
effect
resist
mutat
viru
strain
furthermor
combin
therapi
base
drug
exert
unsatisfactori
respons
effici
therefor
studi
aim
develop
new
effici
antihbv
agent
urgent
desir
scorpion
evolv
particular
venom
system
hundr
million
year
evolut
sake
predat
defend
predat
multipl
type
neurotoxin
gener
block
regul
activ
varieti
ion
channel
addit
antimicrobi
peptid
amp
also
major
compon
scorpion
venom
peptid
small
peptid
exert
function
divers
modul
innat
immun
regul
oncogenesi
directli
inhibit
variou
bacteria
virus
fungi
parasit
recent
year
sever
studi
scorpionderiv
antivir
peptid
report
exampl
scorpion
venomderiv
synthet
peptid
report
immedi
interfer
virion
measl
sarscov
influenza
virus
inhibit
hbv
replic
vitro
vivo
activ
mitogenactiv
protein
kinas
mapk
pathway
downregul
mutat
anoth
scorpionderiv
peptid
show
extrem
enhanc
bioavail
antihcv
activ
compar
wildtyp
peptid
addit
anoth
two
scorpion
venom
peptid
also
report
due
inhibitori
activ
herp
simplex
viru
type
thu
scorpion
venom
resourc
novel
antivir
peptid
studi
present
scorpion
defensin
deriv
scorpion
mesobuthu
martensii
karsch
effect
inhibit
hbv
replic
vitro
stood
scorpion
peptid
high
inhibit
rate
hbeag
hbsag
supernat
cell
rel
low
cytotox
investig
cytotox
antihbv
activ
conduct
conclud
inhibitori
activ
hbv
replic
concentrationdepend
select
index
ratio
cc
ic
rel
high
compar
cytotox
furthermor
also
exert
consider
serum
stabil
first
report
scorpion
defensin
novel
antihbv
agent
potenti
futur
modif
applic
fifteen
put
peptid
venom
cdna
librari
four
scorpion
speci
mesobuthu
martensii
heterometru
petersii
chaerilu
tricostatu
chaerilu
tryznai
deriv
peptid
identifi
candid
antimicrobi
agent
prepar
prokaryot
express
techniqu
chemic
synthesi
tabl
antihbv
activ
peptid
determin
measur
concentr
hbeag
figur
hbsag
figur
cell
cultur
medium
cell
elisa
assay
exert
higher
inhibitori
activ
hbeag
hbsag
compar
scorpionderiv
peptid
inhibitori
effect
respect
cytotox
peptid
cell
measur
mtt
assay
figur
treat
h
cell
viabil
cell
indic
rel
low
cytotox
feasibl
develop
candid
antihbv
agent
determin
measur
cytotox
incub
serial
dilut
h
cell
viabil
figur
figur
figur
cell
measur
use
mtt
assay
cytotox
concentr
cc
respect
concentr
viabil
cell
greater
three
kind
cell
line
hemolysi
assay
also
show
viabil
erythrocyt
concentr
lower
figur
data
indic
less
minim
cytotox
suitabl
antihbv
studi
abil
hbv
elisa
assay
hbeag
hbsag
cultur
medium
cell
averag
inhibitori
rate
hbeag
hbsag
respect
c
cytotox
peptid
measur
mtt
assay
cell
viabil
cell
treat
h
denot
p
valu
repres
mean
sem
five
independ
sampl
feasibl
develop
candid
antihbv
agent
determin
measur
cytotox
incub
serial
dilut
h
cell
viabil
figur
figur
figur
cell
measur
use
mtt
assay
cytotox
concentr
respect
concentr
viabil
cell
greater
three
kind
cell
line
hemolysi
assay
also
show
viabil
erythrocyt
concentr
lower
figur
data
indic
less
minim
cytotox
suitabl
antihbv
studi
investig
effect
hbv
replic
vitro
cell
treat
serial
dilut
h
hbeag
hbsag
level
cell
supernat
treat
measur
elisa
assay
shown
figur
b
cellular
supernat
hbeag
hbsag
level
significantli
reduc
dosedepend
manner
inhibitori
concentr
ic
yield
select
index
ratio
cc
ic
respect
tabl
hbv
progeni
dna
supernat
cell
quantit
use
realtim
pcr
realtim
pcr
data
indic
hbv
progeni
dna
cultur
media
also
inhibit
concentrationdepend
manner
ic
figur
select
index
tabl
thu
reduc
level
hbv
antigen
hbv
progeni
dna
cell
cultur
supernat
concentrationdepend
manner
investig
effect
hbv
replic
vitro
cell
treat
serial
dilut
h
hbeag
hbsag
level
cell
supernat
treat
measur
elisa
assay
shown
figur
b
cellular
supernat
hbeag
hbsag
level
significantli
reduc
dosedepend
manner
inhibitori
concentr
yield
select
index
ratio
respect
tabl
hbv
progeni
dna
supernat
cell
quantit
use
realtim
pcr
realtim
pcr
data
indic
hbv
progeni
dna
cultur
media
also
inhibit
concentrationdepend
manner
figur
select
index
tabl
thu
reduc
level
hbv
antigen
hbv
progeni
dna
cell
cultur
supernat
concentrationdepend
manner
level
intracellular
hbv
viral
protein
measur
western
blot
analysi
similar
effect
cell
cultur
supernat
intracellular
hbsag
figur
almost
undetect
seem
extrem
strong
inhibitori
activ
hbx
protein
figur
cell
treat
slight
band
hbx
protein
hbx
protein
cell
total
undetect
treatment
inhibitori
activ
hbv
core
figur
hbv
rt
figur
seem
lower
compar
hbsag
hbx
protein
still
exert
significantli
concentrationdepend
inhibit
result
suggest
inhibitori
activ
intracellular
hbv
viral
protein
minim
cytotox
concentr
inhibitori
effect
dosedepend
level
intracellular
hbv
viral
protein
measur
western
blot
analysi
similar
effect
cell
cultur
supernat
intracellular
hbsag
figur
also
inhibit
dosedepend
manner
treat
hbsag
almost
undetect
seem
extrem
strong
inhibitori
activ
hbx
protein
figur
cell
treat
slight
band
hbx
protein
hbx
protein
cell
total
undetect
treatment
inhibitori
activ
hbv
core
figur
hbv
rt
figur
seem
lower
compar
hbsag
hbx
protein
still
exert
significantli
concentrationdepend
inhibit
result
suggest
inhibitori
activ
intracellular
hbv
viral
protein
minim
cytotox
concentr
inhibitori
effect
dosedepend
serum
stabil
test
inhibitori
activ
hbeag
hbsag
supernat
incub
fb
less
h
incub
serum
h
less
inhibitori
rate
hbeag
hbsag
similar
rate
serumuntr
slight
decreas
inhibitori
ratio
treat
serum
h
inhibitori
ratio
hbeag
still
respect
figur
meanwhil
inhibitori
ratio
hbsag
respect
figur
result
suggest
high
serum
stabil
serum
stabil
test
inhibitori
activ
hbeag
hbsag
supernat
incub
fb
less
h
incub
serum
h
less
inhibitori
rate
hbeag
hbsag
similar
rate
serumuntr
slight
decreas
inhibitori
ratio
treat
serum
h
inhibitori
ratio
hbeag
still
respect
figur
meanwhil
inhibitori
ratio
hbsag
respect
figur
result
suggest
high
serum
stabil
applic
interferon
limit
side
effect
nucleotid
analog
treatment
lamivudin
potenti
induc
mutat
viral
polymeras
prompt
drugresist
viru
strain
thu
demand
develop
new
potenti
antihbv
drug
still
urgent
recent
year
mani
newli
discov
design
antihbv
compound
organ
molecul
report
cyclosporin
report
inhibit
hbv
hdv
entri
stage
interf
ntcp
sodium
taurochol
cotransport
polypeptid
acyl
peptid
deriv
larg
viral
surfac
protein
inhibit
hbv
infect
extrem
low
insect
defensin
small
cation
peptid
compos
amino
acid
residu
commonli
contain
six
cystein
broad
spectrum
antimicrobi
activ
insect
defensin
involv
bacteria
fungi
even
parasit
sever
scorpion
defensin
defensinlik
antimicrobi
peptid
discov
kda
scorpion
defensin
purifi
present
structur
similar
insect
defensin
scorpion
toxin
anoth
kda
scorpion
defensin
sd
express
yeast
vitro
synergist
activ
convent
antibiot
identifi
experiment
result
show
exert
consider
inhibitori
activ
hbv
replic
decreas
product
hbeag
hbsag
hbv
dna
cell
cultur
medium
product
intracellular
hbsag
hbv
core
protein
hbx
protein
hbv
rt
inhibit
concentrationdepend
compar
high
antihbv
activ
mtt
assay
indic
low
cytotox
cell
cell
cell
cell
stabl
transfer
cell
line
hbv
genom
select
index
valu
high
addit
also
exert
extrem
low
hemolyt
activ
human
erythrocyt
serum
stabil
measur
inhibitori
rate
hbeag
hbsag
incub
serum
serial
time
point
slight
decreas
inhibitori
activ
hbeag
hbsag
h
incub
thought
strong
serum
stabil
best
knowledg
report
antivir
peptid
deriv
scorpion
venom
shortchain
polypeptid
amino
acid
residu
without
disulfid
bridg
typic
sequenc
predict
structur
characterist
defensin
first
scorpion
defensin
experiment
evid
antivir
activ
worth
mention
scorpion
defensin
inhibit
hbv
replic
cultur
system
among
test
peptid
scorpion
venom
differ
non
applic
interferon
limit
side
effect
nucleotid
analog
treatment
lamivudin
potenti
induc
mutat
viral
polymeras
prompt
drugresist
viru
strain
thu
demand
develop
new
potenti
antihbv
drug
still
urgent
recent
year
mani
newli
discov
design
antihbv
compound
organ
molecul
report
cyclosporin
report
inhibit
hbv
hdv
entri
stage
interf
ntcp
sodium
taurochol
cotransport
polypeptid
acyl
peptid
deriv
larg
viral
surfac
protein
inhibit
hbv
infect
extrem
low
ic
insect
defensin
small
cation
peptid
compos
amino
acid
residu
commonli
contain
six
cystein
broad
spectrum
antimicrobi
activ
insect
defensin
involv
bacteria
fungi
even
parasit
sever
scorpion
defensin
defensinlik
antimicrobi
peptid
discov
kda
scorpion
defensin
purifi
present
structur
similar
insect
defensin
scorpion
toxin
anoth
kda
scorpion
defensin
sd
express
yeast
vitro
synergist
activ
convent
antibiot
identifi
experiment
result
show
exert
consider
inhibitori
activ
hbv
replic
decreas
product
hbeag
ic
hbsag
ic
hbv
dna
ic
cell
cultur
medium
product
intracellular
hbsag
hbv
core
protein
hbx
protein
hbv
rt
inhibit
concentrationdepend
compar
high
antihbv
activ
mtt
assay
indic
low
cytotox
addit
also
exert
extrem
low
hemolyt
activ
human
erythrocyt
serum
stabil
measur
inhibitori
rate
hbeag
hbsag
incub
serum
serial
time
point
slight
decreas
inhibitori
activ
hbeag
hbsag
h
incub
thought
strong
serum
stabil
best
knowledg
report
antivir
peptid
deriv
scorpion
venom
shortchain
polypeptid
amino
acid
residu
without
disulfid
bridg
typic
sequenc
predict
structur
characterist
defensin
first
scorpion
defensin
experiment
evid
antivir
activ
worth
mention
scorpion
defensin
inhibit
hbv
replic
cultur
system
among
test
peptid
scorpion
venom
differ
nonact
peptid
short
linear
peptid
crosslink
disulfid
bridg
scorpion
defensin
deduc
strong
serum
stabil
short
linear
peptid
partial
confirm
result
strong
serum
stabil
antihbv
test
meanwhil
phenomenon
possibl
relat
antivir
mechan
although
antivir
mechan
linear
peptid
variou
short
linear
peptid
may
inhibit
viru
infect
replic
interact
viral
envelop
surfac
capsid
destroy
structur
virion
howev
cell
line
use
antivir
experi
studi
deriv
human
hepatoblastoma
hbv
genom
stabli
incorpor
host
genom
hbv
replic
therefor
could
continu
produc
infecti
hbv
virion
success
infect
hbv
particl
addit
recent
group
also
report
effect
select
inhibit
growth
gramposit
bacteria
includ
standard
antibioticresist
strain
block
potassium
channel
neurotoxinlik
poreblock
mode
thu
first
report
multifunct
defensin
three
differ
aspect
bioactiv
whether
intern
relat
three
biolog
function
deserv
research
explor
futur
express
use
prokaryot
express
system
laboratori
peptid
synthes
use
solidphas
synthesi
method
amid
cterminu
puriti
chinapeptid
co
ltd
shanghai
china
dulbecco
modifi
eagl
medium
dmem
invitrogen
foster
ca
usa
supplement
volvol
fetal
bovin
serum
fb
gibco
foster
ca
usa
unitsml
penicillin
streptomycin
use
cultur
three
cell
line
cell
cultur
carbon
dioxid
incub
cell
seed
plate
cell
per
well
cultur
dmem
contain
fb
co
h
peptid
ad
medium
serial
concentr
concentr
rang
five
repetit
set
concentr
h
incub
mtt
solut
mgml
pb
buffer
invitrogen
foster
ca
usa
ad
medium
well
plate
incub
co
h
medium
replac
dmso
complet
dissolv
precipit
crystal
purpl
formazan
plate
gentli
shaken
min
room
temperatur
absorb
wavelength
nm
measur
use
micropl
reader
biotek
winooski
vt
usa
erythrocyt
obtain
fresh
human
blood
centrifug
min
wash
hepe
buffer
three
time
erythrocyt
resuspend
normal
salin
seed
plate
cell
per
well
ad
serial
concentr
use
posit
control
normal
salin
use
neg
control
incub
h
supernat
collect
centrifug
min
absorb
hemoglobin
measur
wavelength
nm
cell
seed
plate
cell
per
well
incub
h
cell
treat
variou
concentr
cultur
anoth
h
hbeag
hbsag
level
quantit
use
enzym
link
immunoassay
elisa
kit
hbv
dna
cultur
medium
extract
measur
use
realtim
pcr
qiagen
valencia
ca
usa
cell
resuspend
radioimmunoprecipit
ripa
assay
buffer
mm
trishcl
ph
mm
sodium
chlorid
nonidet
sodium
deoxychol
phenylmethylsulfonyl
fluorid
pmsf
incub
ice
min
fulli
lysi
cell
lysat
electrophores
sodium
dodecyl
sulfatepolyacrylamid
sd
gel
transfer
nitrocellulos
membran
millipor
darmstadt
germani
antibodi
use
probe
follow
mous
monoclon
antihbsag
incub
fb
ddh
h
h
h
h
ad
cell
cell
incub
co
h
concentr
hbeag
hbsag
detect
use
elisa
antivir
activ
evalu
data
shown
deviat
least
three
separ
experi
statist
signific
test
use
twotail
student
ttest
ic
cc
hc
calcul
use
statist
product
servic
solut
spss
softwar
version
ibm
armonk
ny
usa
follow
avail
onlin
tabl
scorpion
deriv
candid
antimicrobi
peptid
deriv
peptid
